CLAIMS

1. Solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

2. Pharmaceutical composition according to Claim 1, characterized in that the benzofuran derivative with antiarrhythmic activity is dronedarone or one of the pharmaceutically acceptable salts thereof.

3. Pharmaceutical composition according to Claim 1, characterized in that the benzofuran derivative with antiarrhythmic activity is amiodarone or one of the pharmaceutically acceptable saltfs thereof.

4. Pharmaceutical composition according to one of Claims 1 to 3, characterized in that the pharmaceutically acceptable salt is the hydrochloride.

5. Pharmaceutical composition according to one of Claims 1 to 4, characterized in that the nonionic hydrophilic surfactant is chosen from poloxamers, polyethyoxylated castor oils, ethoxylated polysorbates and polyethylene hydroxystearates.

6. Pharmaceutical composition according to Claim 5, characterized in that the nonionic hydrophilic surfactant is chosen from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the products Cremophor® RH 40 and Solutol® HS15.

7. Pharmaceutical composition according to Claim 5 or 6, characterized in that the nonionic hydrophilic surfactant is poloxamer 407.

8. Pharmaceutical composition according to one of Claims 1 to 7, characterized in that the nonionic hydrophilic agent is present in a proportion of from 1% to 50% by weight of the active principle in base form.

9. Pharmaceutical composition according to Claim 8, in tablet or gelatin capsule form, characterized in that the nonionic hydrophilic surfactant is present in a proportion of from 1% to 20% by weight of the active principle in base form.

10. Pharmaceutical composition according to Claim 9, in tablet or gelatin capsule form, characterized in that the nonionic hydrophilic surfactant is present in a proportion of from 5% to 15% by weight of the active principle in base form.

11. Pharmaceutical composition according to one of Claims 1 to 10, characterized in that it contains from 50 to 500 mg of active principle.

12. Pharmaceutical composition according to Claim 11, in tablet or gelatin capsule form, characterized in that it contains from 200 to 400 mg of active principle.

13. Pharmaceutical composition according to one of Claims 1 to 12, in tablet or gelatin capsule form, characterized in that it contains from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.